Niraparib (Zejula) for Ovarian Cancer - Details
( Last Updated : September 21, 2020)
NOC Status at Filing:
As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Reimburse with clinical criteria and/or conditions
Final Recommendation Issued (target date):
Final Recommendation Issued:
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.